Project Grant R01HD121601
- The National Institute of Child Health and Human Development awarded Marshall University Research Corporation $147,500 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate epigenetic regulation of CXCR4 in endometriosis. The research examines aberrant promoter methylation dynamics of CXCR4, a master regulator involved in endometrial cell migration, stem cell trafficking, and lesion formation in endometriosis. The project aims...
- The National Institute of Child Health and Human Development awarded The Trustees of Columbia University in the City of New York $444,824 on August 20, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to engineer human pluripotent stem cell (HPSC)-derived endometrial organoids for modeling regeneration and disease mechanisms. The project will develop an innovative platform that recapitulates physiological interactions and developmental trajectories...
- The National Institute of Child Health and Human Development awarded Trustees of Tufts College $351,945 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate inflammation resolution mechanisms in endometrial health and disease. The research dissects how specialized pro-resolving mediators, a class of lipid-derived molecules that orchestrate inflammation resolution, operate in the human endometrium across the menstrual cycle. The...
- The National Institute of Neurological Disorders and Stroke awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $3.637 million on August 24, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to identify pro-resolving lipid mediator receptors as therapeutic targets for endometriosis-associated pain. The project runs through April 30, 2030, and is performed in Massachusetts. The research aims to identify the most active specialized...
- The National Institute of Child Health and Human Development awarded the University of Cincinnati Sponsored Research Services Division $696,598 on July 15, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate the role of environmental phthalates in endometriosis development. The research uses a mouse model of endometriosis to examine how high and low molecular weight phthalates—bis(2-ethylhexyl) phthalate (DEHP) and dibutyl phthalate...
- The National Institute of Child Health and Human Development awarded the University of Missouri System $500,000 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate molecular mechanisms underlying endometriosis-associated infertility. The award is a Project Grant (R56HD122660). The research addresses the role of the transcription factor FOXA2 in endometriosis development and related infertility. The investigative team will...
- The National Institute of Child Health and Human Development awarded the University of Texas at Dallas $608,387 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate vaginal microbiome-nociceptor interactions in endometriosis pain. The research uses mouse models of endometriosis, intravaginal antibiotic treatment, vaginal microbiota transplant paradigms, and probiotic bacterial administration to explore the bidirectional...
- The National Institute of Child Health and Human Development awarded Michigan State University $3.548 million on September 12, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct transcriptomic analyses of early endometriotic lesion development. The recipient, doing business as Henry Ford Health+Michigan State University Health Sciences, will integrate single-cell, spatial, and bulk transcriptomics analyses of peritoneal endometriotic lesions...
- The National Institute of Neurological Disorders and Stroke awarded the University of Florida $187,317 on July 20, 2026, to characterize the endometriosis microbiome and metabolomic pain phenotype under the Drug Use and Addiction Research Programs (CFDA 93.279). The project stratifies individuals with endometriosis into treatment-responsive groups by identifying differences in microbial and NAD+ metabolomic patterns associated with differing pain characteristics, quality of life, psychological...
- The National Institute of Child Health and Human Development (NICHD) of the Department of Health and Human Services awarded North Carolina State University $673,394 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to decode epigenetic networks that orchestrate endometrial function. The project addresses molecular mechanisms underlying uterine dysfunction in recurrent implantation failure and recurrent pregnancy loss, which remain major...
The National Institute of Child Health and Human Development awarded Oregon State University $444,498 on August 18, 2026, to develop nanoparticle-mediated chemodynamic therapy for endometriosis under the Child Health and Human Development Extramural Research program (CFDA 93.865, Project Grant R01HD121601). Endometriosis affects approximately 176 million women worldwide, causing severe pelvic pain and infertility with no cure. Current clinical therapies cause infertility, and surgical lesion excision carries a 27 percent recurrence rate, often requiring multiple procedures. The research applies chemodynamic therapy—an emerging cancer treatment using nanomaterials containing iron or other transition metals—to endometriotic tissue. CDT catalyzes conversion of elevated hydrogen peroxide levels in cells into cytotoxic hydroxyl radicals through Fenton reactions, selectively destroying malignant or diseased cells while minimizing damage to healthy tissue. Endometriosis cells produce elevated hydrogen peroxide and reactive oxygen species similar to cancer cells, and endometriotic lesions contain high iron levels from repeated bleeding cycles that catalyze hydroxyl radical production. Preliminary studies validated CDT feasibility for endometriosis treatment. The project aims to develop a non-surgical approach for removing endometriotic lesions that also improves endometriosis-associated pelvic pain. Performance takes place in Corvallis, Oregon. The period of performance extends from August 18, 2026, through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $444.5k | 8/20/26 |